For Healthcare Professionals Outside the US, UK, China, and Germany
Order Now
NIOX® Customer Experience
+46 18 32 88 37
Monday-Friday, 8AM-5PM CET

Experience the Impact With NIOX VERO®

NIOX VERO with 55 ppb measurement

Routine FeNO Monitoring to aid in treatment optimization

NIOX VERO gives you an objective and accurate measurement of airway inflammation right at the point of care.1

  • Establish the patient's baseline and personal best FeNO level2,3
  • Assess adherence to ICS treatment4,5
  • Optimise the use of ICS and adjust accordingly4,6
  • Aids in diagnosis and helps to identify patients who may benefit from biologics7
  • To date, over 20 million tests have been performed using a NIOX device8

An accurate FeNO result in a single measurement with results in approximately

1 minute

NIOX-Guided Treatment Significantly Reduced Exacerbation Rates4,9

In Children

50% reduction chart

*An exacerbation was defined as an episode of progressive increased shortness of breath, coughing, wheezing, or chest tightness, or a combination of these symptoms.9

In Adults

46% reduction chart

Moderate exacerbations were defined as deterioration in symptoms with the need to step up controller treatment for at least 2 days, with or without a concomitant clinic visit or contact. Severe exacerbations were defined as worsening in asthma that necessitated a course of oral corticosteroids.4

References: 1. Spahn JD, Malka J, Szefler SJ. Current application of exhaled nitric oxide in clinical practice. J Allergy Clin Immunol. 2016; 138:1296-1298. 2. Smith AD, Cowan JO, Taylor RD. Exhaled nitric oxide levels in asthma: Personal best versus reference values. J Allergy Clin Immunol. 2009 Oct;124(4):714-8. 3. Dweik RA, Boggs PB, Erzurum SC, et al; on behalf of the American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-615. 4. Syk J, Malinovschi A, Johansson G, et al. Anti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized, controlled trial. J Allergy Clin Immunol Pract. 2013;1(6):639-648. 5. Beck-Ripp J, Griese M, Arenz S, Köring C, Pasqualoni B, Bufler P. Changes of exhaled nitric oxide during steroid treatment of childhood asthma. Eur Respir J. 2002;19(6):1015-1019. 6. Smith AD, Cowan JO, Brassett KP, Herbison P, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005;352(21):2163-2173. 7. Darveaux J, Busse WW. Biologics in asthma—the next step towards personalized treatment. J Allergy Clin Immunol Pract. 2015;3(2):152-161. 8. Data on file. Circassia Ltd May 2019. 9. Peirsman EJ, Carvelli TJ, Hage PY, et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatr Pulmonol. 2014;49(7):624-631.